PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), today announced the advancement of their anti-cancer compound research and development. The culmination of a series of favorable test results conducted over several months have allowed the company to justifiably expand their cancer research efforts which includes the designing of an IV formulation of their key compound.
